Testing and diagnosis of hepatitis B (HBV) and C (HCV) infection is the gateway for access to both prevention and treatment services, and is a crucial component of an effective response to the hepatitis epidemic. Early identification of persons with chronic HBV or HCV infection enables them to recei...ve the necessary care and treatment to prevent or delay progression of liver disease. Testing also provides an opportunity to link people to interventions to reduce transmission, through counselling on risk behaviours and provision of prevention commodities (such as sterile needles and syringes) and hepatitis B vaccination.
more
Investigación original / Original research
Rev Panam Salud Publica 35(1), 2014
J Hepatol (2017), http://dx.doi.org/10.1016/j.jhep.2017.03.021
Also available in Arabic, German, Greek, Italian, Croatian, Polish, Romanian, Russian, Serbian, Spanish, Turkish and Vietnamese. Other language versions can be found on the website of the German liver foundation: http://www.deutsche-leberstiftung.de/hilfe/informationsmaterialien/faltblätter.
Also available in English, Bulgarian, German, French, Greek, Italian, Croatian, Polish, Romanian, Russian, Serbian (kyrillic or latin), Spanish, Turkish, Hungarian on http://www.lgl.bayern.de/gesundheit/infektionsschutz/asylbewerber_gesundheit/index.htm under the section "Asylbewerber und Gesundhei...t".
more
Also available in Arabic, German, Greek, Italian, Croatian, Polish, Romanian, Russian, Serbian, Spanish, Turkish and Vietnamese. Other language versions can be found on the website of the German liver foundation: http://www.deutsche-leberstiftung.de/hilfe/informationsmaterialien/faltblätter.
With the goal of ending viral hepatitis as a public health threat by 2030, the Regional Action Plan will provide an actionable framework for implementing evidence-based interventions at scale. It will be informed through strategic monitoring of the response, that must be equitable and sustainable an...d allow for innovations for acceleration and reaching out to all in need with health services. A major reduction in prices of newer drugs to potentially cure hepatitis C offers an added opportunity to work towards its elimination.
more
Clinical guideline, Methods, Evidence and Recommendations
In this guideline the following is covered: information needs of people with chronic hep
titis B and their carers; where children, young people and adults with chronic hepatitis B a-
should be assessed; assessment of liver disease, includi...ng the use of non-invasive tests and genotype testing; criteria for offering antiviral treatment; the efficacy, safety and cost effectiveness of currently available treatments; selection of first-line therapy; management of treatment failure or drug resistance; prophylactic treatment during im-
munosuppressive therapy; and monitoring for treatment response
more
Direct acting antivirals (DAAs) have revolutionized treatment for hepatitis C. Combi-
nations of DAAs can cure infection with HCV in 12 weeks, are highly effective and
have limited side-effects. Affordability of DAAs has improved significantly, but access remains lim-
i...ted. Initially, due to their high prices, affordability of DAAs was limited in high-, middle- and low-
income countries alike. Now there is a divide between those countries where, because of intellectual
property barriers, prices have remained (very) high and other countries where generics are, or can be,
available at much lower prices. The result is a dual market
more
Overcoming barriers in low- and middle-income countries
For the first time, this year’s report includes information on hepatitis C diagnostics. With a focus on selected countries with diverse HCV epidemics, the report provides updates on the various dimensions of access to HCV diagnostics and pha...rmaceutical products, including product pricing, the regulatory environment and patent status, which together shape the national hepatitis response in different settings. It highlights key areas for action by ministries of health and other government decision-makers, pharmaceutical manufacturers and technical partners.
more
Vaksen Kont Epatit AKi Sa Ou Bezwen Konnen
En estas directrices se actualiza la sección de recomendaciones sobre la prevención de la transmisión maternoinfantil de las Directrices para la prevención, la atención y el tratamiento de la infección crónica por el virus de la hepatitis B, publicadas por la OMS en el 2015, y se centra la at...ención en el uso de la profilaxis con antivirales en el embarazo. Su finalidad es proporcionar orientación respaldada por la evidencia acerca del uso de la profilaxis con antivirales durante el periparto en embarazadas que han dado positivo al HBsAg a efectos de prevenir la transmisión maternoinfantil del VHB. Los principales destinatarios son los funcionarios de los ministerios de salud que formulan las políticas nacionales y las directrices sobre la prevención de la transmisión maternoinfantil del VHB en todos los países, pero sobre todo en los de ingresos bajos y medianos. Asimismo, podrías ser útiles para los miembros del personal de salud que tratan a las personas con la infección por el VHB, así como a los que prestan atención a las embarazadas y los lactantes.
more
Viral hepatitis is defined as inflammation of the liver cells due to viral infection. The burden of liver disease in South Africa is mostly underestimated as viral hepatitis, in particular chronic infection, is a silent and neglected cause of morbidity and mortality. However, the burden of disease i...s likely substantial given the prevalence of chronic viral hepatitis. This burden is further compounded by the lack of screening and access to care and treatment as well as inadequate disease surveillance, human and financial resources.
The National Guidelines for the Management of Viral Hepatitis were developed, with the purpose to:
inform healthcare workers in the public and private sectors about the disease, its epidemiology in South Africa and current methods of diagnosis and therapy
strengthen the healthcare response to viral hepatitis
empower communicable diseases workers and stakeholders to make informed decisions regarding appropriate and cost effective interventions
more
This document provides interim guidance to countries on testing considerations and strategies for suspect cases of severe acute hepatitis of unknown aetiology in children. It is primarily intended for clinical, programmatic, laboratory and diagnostic stakeholders across Member States and national pu...blic health authorities involved in the identification and investigation of cases of severe acute hepatitis in children.
This document is part of a package of guidance for this event, which includes suggested minimum reporting variables and a clinical Case Report Form support Member States with case investigation and reporting.
more
Este documento ofrece una orientación provisional a los países sobre las consideraciones y estrategias de análisis para los casos sospechosos de hepatitis aguda grave de etiología desconocida en niños. Está dirigido principalmente a las partes interesadas en el ámbito clínico, programático,... de laboratorio y de diagnóstico de los Estados miembros y a las autoridades nacionales de salud pública que participan en la identificación e investigación de casos de hepatitis aguda grave en niños.
more
The position papers are intended for use by national public health officials and managers of immunization programmes. They may also be of interest to international funding agencies, vaccine advisory groups, vaccine manufacturers, health professionals, researchers, the scientific media and the genera...l public.
Les notes de synthèse s’adressent aux responsables nationaux de la santé publique et aux administrateurs des programmes de vaccination, mais elles peuvent également présenter un intérêt pour les organismes internationaux de financement, les groupes consultatifs sur la vaccination, les fabricants de vaccins, les professionnels de la santé, les chercheurs, les médias scientifiques et le grand public.
more
Building on the 2021 Interim guidance, this second version and update, incorporates the lessons and feedback from the hepatitis pilots that successfully demonstrated the feasibility of measuring hepatitis B and C impact targets to demonstrate elimination, whilst highlighting challenges caused by hig...h disease burden in some countries, as well as delays in reaching mortality targets due to the long natural history of disease progression to liver cirrhosis and hepatocellular carcinoma.
The path to elimination provides a framework with 3 levels of achievements for which WHO certification is available. Each stepwise progression from bronze to silver to gold tiers will promote an iterative expansion of prevention, diagnosis and treatment services for viral hepatitis services and strengthen measurement systems to support attainment of the 2030 elimination goals.
This updated version also includes changes, clarifications and new guidance on alternative measurement approaches for country validation of elimination. Through the validation process, WHO and partners continue to provide country support for strengthening health system capacity and patient-centred services that respect and protect the human rights of people living with viral hepatitis and ensures meaningful engagement of communities in the national, regional and global viral hepatitis response.
more
Hepatitis B (HBV) infection is a major public health problem and cause of chronic liver disease.
The 2024 HBV guidelines provide updated evidence-informed recommendations on key priority topics. These include expanded and simplified treatment criteria for adults but now also for adolescents; expa...nded eligibility for antiviral prophylaxis for pregnant women to prevent mother-to-child transmission of HBV; improving HBV diagnostics through use of point-of-care HBV DNA viral load and reflex approaches to HBV DNA testing; who to test and how to test for HDV infection; and approaches to promote delivery of high-quality HBV services, including strategies to promote adherence to long-term antiviral therapy and retention in care.
The 2024 guidelines include 11 updated chapters with new recommendations and also update existing chapters without new recommendations, such as those on treatment monitoring and surveillance for liver cancer.
more